Invention Grant
- Patent Title: BSL2v2c2-Ig polypeptides
-
Application No.: US15218699Application Date: 2016-07-25
-
Publication No.: US10308702B2Publication Date: 2019-06-04
- Inventor: Glen Eugene Mikesell , Han Chang , Robert James Peach
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Comapny
- Current Assignee: Bristol-Myers Squibb Comapny
- Current Assignee Address: US NJ Princeton
- Agent Bo Han
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K16/28 ; C07K19/00 ; A61K38/17 ; A61K39/395 ; G01N33/50 ; A61K38/00 ; A61K39/00

Abstract:
The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Public/Granted literature
- US20170190759A1 BSL2v2c2-Ig polypeptides Public/Granted day:2017-07-06
Information query